|
1
|
Hudson BG, Tryggvason K, Sundaramoorthy M
and Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type
IV collagen. New Engl J Med. 348:2543–2556. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kashtan C: Alport syndrome: Facts and
opinions. F1000Res. 6(50)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Naylor RW, Morais M and Lennon R:
Complexities of the glomerular basement membrane. Nat Rev Nephrol.
17:112–127. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kruegel J, Rubel D and Gross O: Alport
syndrome-insights from basic and clinical research. Nat Rev
Nephrol. 9:170–178. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Crockett DK, Pont-Kingdon G, Gedge F,
Sumner K, Seamons R and Lyon E: The Alport syndrome COL4A5 variant
database. Hum Mutat. 31:E1652–E1657. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kashtan CE: Alport syndrome: Achieving
early diagnosis and treatment. Am J Kidney Dis. 77:272–279.
2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fallerini C, Dosa L, Tita R, Del Prete D,
Feriozzi S, Gai G, Clementi M, Manna AL, Miglietti N, Mancini R, et
al: Unbiased next generation sequencing analysis confirms the
existence of autosomal dominant Alport syndrome in a relevant
fraction of cases. Clin Genet. 86:252–257. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Omachi K and Miner JH: Alport syndrome
therapeutics: Ready for prime-time players. Trends Pharmacol Sci.
40:803–806. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xu Y, Lin Z, Tang C, Tang Y, Cai Y, Zhong
H, Wang X, Zhang W, Xu C, Wang J, et al: A new massively parallel
nanoball sequencing platform for whole exome research. BMC
Bioinformatics. 20:153–161. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Huang J, Liang X, Xuan Y, Geng C, Li Y, Lu
H, Qu S, Mei X, Chen H, Yu T, et al: A reference human genome
dataset of the BGISEQ-500 sequencer. Gigascience. 6:1–9.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Richards CS, Bale S, Bellissimo DB, Das S,
Grody WW, Hegde MR, Lyon E and Ward BE: ACMG recommendations for
standards for interpretation and reporting of sequence variations:
Revisions 2007. Genet Med. 10:294–300. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Goka S, Copelovitch L and Levy Erez D:
Long-term outcome among females with Alport syndrome from a single
pediatric center. Pediatr Nephrol. 36:945–951. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Imafuku A, Nozu K, Sawa N, Hasegawa E,
Hiramatsu R, Kawada M, Hoshino J, Tanaka K, Ishii Y, Takaichi K, et
al: Autosomal dominant form of type IV collagen nephropathy exists
among patients with hereditary nephritis difficult to diagnose
clinicopathologically. Nephrology (Carlton). 23:940–947.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Marcocci E, Uliana V, Bruttini M, Artuso
R, Silengo MC, Zerial M, Bergesio F, Amoroso A, Savoldi S, Pennesi
M, et al: Autosomal dominant Alport syndrome: Molecular analysis of
the COL4A4 gene and clinical outcome. Nephrol Dial Transplant.
24:1464–1471. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ninomiya Y, Kagawa M, Iyama K, Naito I,
Kishiro Y, Seyer JM, Sugimoto M, Oohashi T and Sado Y: Differential
expression of two basement membrane collagen genes, COL4A6 and
COL4A5, demonstrated by immunofluorescence staining using
peptide-specific monoclonal antibodies. J Cell Biol. 130:1219–1229.
1995.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Heidet L, Arrondel C, Forestier L,
Cohen-Solal L, Mollet G, Gutierrez B, Stavrou C, Gubler MC and
Antignac C: Structure of the human type IV collagen gene COL4A3 and
mutations in autosomal Alport syndrome. J Am Soc Nephrol.
12:97–106. 2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liu Y: New insights into
epithelial-mesenchymal transition in kidney fibrosis. J Am Soc
Nephrol. 21:212–222. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yeo J, Qiu Y, Jung GS, Zhang YW, Buehler
MJ and Kaplan DL: Adverse effects of Alport syndrome-related Gly
missense mutations on collagen type IV: Insights from molecular
simulations and experiments. Biomaterials.
240(119857)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Inoue Y, Nishio H, Shirakawa T, Nakanishi
K, Nakamura H, Sumino K, Nishiyama K, Iijima K and Yoshikawa N:
Detection of mutations in the COL4A5 gene in over 90% of male
patients with X-linked Alport's syndrome by RT-PCR and direct
sequencing. Am J Kidney Dis. 34:854–862. 1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gross O, Netzer KO, Lambrecht R, Seibold S
and Weber M: Meta-analysis of genotype-phenotype correlation in
X-linked Alport syndrome: Impact on clinical counselling. Nephrol
Dial Transplant. 17:1218–1227. 2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Savige J, Ariani F, Mari F, Bruttini M,
Renieri A, Gross O, Deltas C, Flinter F, Ding J, Gale DP, et al:
Expert consensus guidelines for the genetic diagnosis of Alport
syndrome. Pediatr Nephrol. 34:1175–1189. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Artuso R, Fallerini C, Dosa L, Scionti F,
Clementi M, Garosi G, Massella L, Epistolato MC, Mancini R, Mari F,
et al: Advances in Alport syndrome diagnosis using next-generation
sequencing. Eur J Hum Genet. 20:50–57. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Morinière V, Dahan K, Hilbert P, Lison M,
Lebbah S, Topa A, Bole-Feysot C, Pruvost S, Nitschke P, Plaisier E,
et al: Improving mutation screening in familial hematuric
nephropathies through next generation sequencing. J Am Soc Nephrol.
25:2740–2751. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tran KT, Le VS, Vu CD and Nguyen LT: A
novel de novo variant of LAMA2 contributes to merosin deficient
congenital muscular dystrophy type 1A: Case report. Biomed Rep.
12:46–50. 2020.PubMed/NCBI View Article : Google Scholar
|
